Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ocular Therapeutix, Inc.    OCUL

OCULAR THERAPEUTIX, INC.

(OCUL)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/09/2019 10/10/2019 10/11/2019 10/14/2019 10/15/2019 Date
2.86(c) 2.8(c) 2.94(c) 3.06(c) 3.3(c) Last
630 075 373 664 527 809 343 108 399 714 Volume
-2.72% -2.10% +5.00% +4.08% +7.84% Change
More quotes
Financials (USD)
Sales 2019 9,54 M
EBIT 2019 -82,4 M
Net income 2019 -85,6 M
Debt 2019 -
Yield 2019 -
Sales 2020 63,1 M
EBIT 2020 -37,3 M
Net income 2020 -54,9 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -1,77x
P/E ratio 2020 -3,14x
Capi. / Sales2019 16,3x
Capi. / Sales2020 2,47x
Capitalization 156 M
More Financials
Company
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for... 
More about the company
Surperformance© ratings of Ocular Therapeutix, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on OCULAR THERAPEUTIX, INC.
10/02OCULAR THERAPEUTIX : Announces Permanent J-Code for DEXTENZA Effective October 1..
AQ
10/01OCULAR THERAPEUTIX : Announces Permanent J-Code for DEXTENZA® (dexamethasone oph..
BU
09/27OCULAR THERAPEUTIX : to Present at the 2019 Cantor Global Healthcare Conference
AQ
09/26OCULAR THERAPEUTIX : trade; to Present at the 2019 Cantor Global Healthcare Conf..
BU
09/24OCULAR THERAPEUTIX, INC : Other Events (form 8-K)
AQ
09/24OCULAR THERAPEUTIX : trade; Announces First Patient Dosed in Phase 3 Clinical Tr..
BU
08/30OCULAR THERAPEUTIX : to Present at the 2019 Wells Fargo Healthcare Conference
AQ
08/29OCULAR THERAPEUTIX : trade; to Present at the 2019 Wells Fargo Healthcare Confer..
BU
08/08OCULAR THERAPEUTIX : Reports Second Quarter 2019 Financial Results and Business ..
AQ
08/07OCULAR THERAPEUTIX : 2Q Earnings Snapshot
AQ
08/07OCULAR THERAPEUTIX : Management's Discussion and Analysis of Financial Condition..
AQ
08/07OCULAR THERAPEUTIX, INC : Results of Operations and Financial Condition, Financi..
AQ
08/07OCULAR THERAPEUTIX : trade; Reports Second Quarter 2019 Financial Results and Bu..
BU
08/01OCULAR THERAPEUTIX : trade; To Report Second Quarter 2019 Financial Results
BU
07/29OCULAR THERAPEUTIX : Announces Early Assignment of Permanent and Specific J-Code..
AQ
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
02:48aDrug Firms In Talks To Settle Lawsuits -- WSJ
DJ
10/15AmerisourceBergen, Cardinal Health, McKesson up After Hours Following WSJ Sto..
DJ
10/15Drug Distributors in Talks to Settle Opioid Litigation for $18 Billion -- 2nd..
DJ
10/15Drug Distributors in Talks to Settle Opioid Litigation for $18 Billion -- Upd..
DJ
10/15Drug Distributors in Talks to Settle Opioid Litigation for $18 Billion
DJ
More sector news : Medical Equipment, Supplies & Distribution - NEC
Chart OCULAR THERAPEUTIX, INC.
Duration : Period :
Ocular Therapeutix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OCULAR THERAPEUTIX, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 9,33  $
Last Close Price 3,30  $
Spread / Highest target 567%
Spread / Average Target 183%
Spread / Lowest Target -9,09%
EPS Revisions
Managers
NameTitle
Antony Mattessich President, Chief Executive Officer & Director
Amarpreet S. Sawhney Executive Chairman
Patricia Kitchen Chief Operating Officer
Donald Notman Chief Financial & Accounting Officer
Peter Jarrett Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
OCULAR THERAPEUTIX, INC.-17.09%156
MEDTRONIC PLC18.94%144 323
BAXTER INTERNATIONAL INC.33.30%44 520
HOYA CORPORATION39.38%31 047
ZIMMER BIOMET HOLDINGS32.94%27 767
TERUMO CORPORATION-43.60%23 040